|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Understanding Time Toxicity: Impact of Treatment Time on Prostate Cancer Patients |
| Daniel Sentana Lledo, MD |
| Ruchika Talwar hosts Daniel Sentana Lledo to discuss the concept of time toxicity in prostate cancer treatment. Time toxicity measures the amount of time patients spend in the healthcare system and how it impacts their survival time gained from therapies. |
|
|
|
|
|
|
|
|
|
|
|
| Rising Out-of-Pocket Costs in Prostate Cancer Screening: A Growing Concern |
| Arnav Srivastava, MD, MPH |
| Arnav Srivastava discusses his research on out-of-pocket costs for prostate cancer screening follow-up among privately insured men. The study reveals that by 2020, 80% of patients face out-of-pocket expenses for diagnostic testing, with costs rising significantly over time. |
|
|
|
|
|
|
|
|
|
|
|
| Reducing Prescription Drug Costs: 4 Online Tools for Urology Patients |
| Benjamin Pockros, MD, MBA |
| Ruchika Talwar interviews Benjamin Pockros about his published work in Urology Practice, which explores online tools to reduce financial toxicity for urology patients. Dr. Pockros presents a framework of four key tools: Medicare Part D Plan Finder, GoodRx, Mark Cuban Cost Plus Drugs Company, and Amazon Pharmacy. |
|
|
|
|
|
|
|
|
|
|
|
| It's Time to Talk About Value-Based Care and Time Toxicity With Our Patients
|
| Cary Stimson, MD
|
| Cary Stimson highlighted the importance of value-based care in bladder cancer, focusing on paying for healthcare that delivers effective outcomes relative to cost. He identified opportunities to improve value, such as using alvimopan for faster recovery after surgery and avoiding costly, low-value interventions like photodynamic TURBT. Dr. Stimson stressed the need for future strategies that address risk-sharing models while balancing quality care and minimizing time toxicity for patients.
|
|
|
|
|
|
|
|
|
|
|
Cost-Utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care - Beyond the Abstract
|
| Daniel Lindsay, Penelope Schofield, Matthew Roberts et al. |
| The Navigate trial evaluated the cost-effectiveness of an online decision aid for men with prostate cancer and their partners, compared to usual care. The study found that Navigate improved quality-adjusted life years (QALYs) and was cost-effective, with its utility increasing as the adoption of active surveillance grew. By enhancing understanding of management options, Navigate helps patients make evidence-driven decisions, potentially increasing active surveillance rates and reducing healthcare costs. |
|
|
|
|
|
The Impact of Venous Thromboembolism Before Open or Minimally-Invasive Radical Cystectomy in the USA: Insurance Claims Data on Perioperative Outcomes and Healthcare Costs - Beyond the Abstract
|
| Roberta Corvino, Francesco Del Giudice, and Benjamin I. Chung |
| A study using U.S. insurance claims data examined the impact of preoperative venous thromboembolism (VTE) on outcomes for bladder cancer patients undergoing radical cystectomy (RC). A prior VTE diagnosis was associated with significantly higher rates of postoperative complications, rehospitalizations, new VTE events, longer hospital stays, and increased healthcare costs. These findings highlight the importance of addressing preoperative VTE risks to optimize patient care and reduce associated costs. |
|
|
|
|
|
Patient Out-of-Pocket Costs for Guideline-Recommended Treatments for Erectile Dysfunction: A Medicare Cost Modeling Analysis - Beyond the Abstract
|
| Vi Nguyen MD, Darshan P. Patel MD & Tung-Chin Hsieh MD, MBA |
| A Medicare-based cost model for erectile dysfunction (ED) treatments revealed significant out-of-pocket (OOP) costs for patients using guideline-recommended therapies. The highest OOP expenses were associated with intra-urethral (IA) prescriptions ($4022 annually) and injectable intracavernosal (ICI) therapies ($3947), while oral PDE5 inhibitors and penile prosthesis (IPP) were more affordable ($696 and $1600, respectively). The study underscores the need for healthcare providers to consider treatment costs in decision-making to improve patient awareness and reduce financial burdens. |
|
|
|
|
|
| Financial Toxicity in Testicular Cancer Treatment, Validated Questionnaire Correlated Software Cost Modeling |
| Peter Sullivan, DO |
| Peter Sullivan presented a study on financial toxicity in the treatment of testicular cancer, comparing retroperitoneal lymph node dissection (RPLND) with chemotherapy. Using a validated questionnaire and a Markov model, the study found that while RPLND has higher initial costs, it is more cost-effective in the long term, with patients experiencing lower financial burden over time compared to chemotherapy, which led to higher cumulative costs due to ongoing treatments and long-term side effects. |
|
|
|
|
|
|
|
|
|
|
